About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Fas
Fas cell surface death receptor
MGI:95484
190 phenotypes from 11 alleles in 40 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Cd19tm1(cre)Cgn/Cd19+
Faslpr/Fastm1Cgn
involves: 129P2/OlaHsd * C57BL/6 * MRL
enlarged lymph nodes J:114948
enlarged spleen J:114948
Cd19tm1(cre)Cgn/Cd19+
Faslpr/Fastm1Cgn
Tg(Cd4-cre)1Cwi/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL
enlarged lymph nodes J:114948
enlarged spleen J:114948
increased double-negative T cell number J:114948
Cd19tm1(cre)Cgn/Cd19+
Fastm1Ach/Fastm1Ach
involves: 129P2/OlaHsd * BALB/c
enlarged spleen J:123556
increased anti-nuclear antigen antibody level J:123556
increased immunoglobulin level J:123556
increased lymphocyte cell number J:123556
Cd19tm1(cre)Cgn/Cd19+
Fastm1Cgn/Fastm1Cgn
B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn
increased anti-single stranded DNA antibody level J:114948
Faslpr-cg/Faslpr-cg
CBA/KlJms-Faslpr-cg/J
abnormal hypersensitivity reaction J:24805, J:81770
abnormal lymph organ size J:24805
abnormal T cell differentiation J:24805
autoimmune response J:24805, J:81770
enlarged lymph nodes J:24805, J:81770
enlarged spleen J:24805
increased anti-nuclear antigen antibody level J:24805
increased autoantibody level J:81770
increased IgG level J:24805, J:81770
increased IgM level J:24805, J:81770
increased immunoglobulin level J:24805
increased spleen weight J:81770
premature death J:24805
Faslpr/Faslpr
AK.MRL-Faslpr
abnormal renal glomerulus morphology J:7454
enlarged lymph nodes J:7454
expanded mesangial matrix J:7454
glomerulonephritis J:7454
increased anti-double stranded DNA antibody level J:7454
increased anti-nuclear antigen antibody level J:7454
increased autoantibody level J:7454
increased immunoglobulin level J:7454
increased mesangial cell number J:7454
lymph node hemorrhage J:7454
lymph node necrosis J:7454
renal glomerular immunoglobulin deposits J:7454
Faslpr/Faslpr
B6.Cg-Apoetm1Unc Faslpr
normal cardiovascular system phenotype J:121671
Faslpr/Faslpr
B6.MRL-Faslpr
abnormal renal glomerulus morphology J:7454
decreased interleukin-2 secretion J:6638
enlarged lymph nodes J:6638, J:7454, J:135036
enlarged spleen J:135036
expanded mesangial matrix J:7454
glomerulonephritis J:7454, J:135036
increased anti-double stranded DNA antibody level J:7454
increased anti-nuclear antigen antibody level J:6638, J:135036
increased autoantibody level J:7454, J:135036
increased double-negative T cell number J:135036
increased immunoglobulin level J:7454
increased mesangial cell number J:7454
lymph node hemorrhage J:7454
lymph node necrosis J:7454
premature death J:6638, J:7454, J:135036
renal glomerular immunoglobulin deposits J:7454, J:135036
Faslpr/Faslpr
B6.MRL-Faslpr/J
abnormal hepatocyte morphology J:135830
abnormal kidney morphology J:132217
abnormal liver physiology J:120559, J:135830
abnormal NK cell physiology J:115033
abnormal renal glomerulus basement membrane morphology J:132217
abnormal splenic cell ratio J:132217
brain inflammation J:120427
CNS inflammation J:120427
decreased B cell apoptosis J:135830
decreased hepatocyte apoptosis J:135830
demyelination J:120427
enlarged lymph nodes J:119584
focal hepatic necrosis J:135830
increased anti-double stranded DNA antibody level J:132217
increased anti-histone antibody level J:132217
increased anti-nuclear antigen antibody level J:132217
increased anti-single stranded DNA antibody level J:132217
increased autoantibody level J:132217
increased follicular B cell number J:132217
increased immature B cell number J:132217
increased marginal zone B cell number J:132217
increased renal glomerulus apoptosis J:132217
increased splenocyte number J:132217
increased susceptibility to bacterial infection J:136745
increased susceptibility to Picornaviridae infection J:120427
increased transitional stage B cell number J:132217
lymph node hyperplasia J:132217
Faslpr/Faslpr
C3.MRL-Faslpr
abnormal interleukin level J:8267
abnormal T cell morphology J:8267
abnormal T cell physiology J:8267
abnormal T cell proliferation J:8267
abnormal vagina weight J:114219
decreased apoptosis J:114219
decreased neuron apoptosis J:124252
normal endocrine/exocrine gland phenotype J:1028
lacrimal gland atrophy J:1028
lacrimal gland inflammation J:1028
salivary gland inflammation J:1028
Faslpr/Faslpr
C3.MRL-Faslpr/J
abnormal airway responsiveness J:106288
abnormal B cell activation J:7454
abnormal renal glomerulus morphology J:7454
abnormal T cell morphology J:7454
decreased eosinophil cell number J:106288
decreased interleukin-2 secretion J:7454
enlarged lymph nodes J:7454
expanded mesangial matrix J:7454
glomerulonephritis J:7454
normal immune system phenotype J:7454
increased anti-double stranded DNA antibody level J:7454
increased anti-nuclear antigen antibody level J:7454
increased apoptosis J:106288
increased autoantibody level J:7454
increased immunoglobulin level J:7454
increased mesangial cell number J:7454
lymph node hemorrhage J:7454
lymph node hyperplasia J:7454
lymph node necrosis J:7454
normal mortality/aging J:120650
premature death J:7454
renal glomerular immunoglobulin deposits J:7454
Faslpr/Faslpr
involves: 129P2/OlaHsd * MRL
abnormal kidney morphology J:45448
abnormal renal glomerulus morphology J:45448
enlarged lymph nodes J:26250
glomerulonephritis J:45448
increased blood urea nitrogen level J:45448
increased double-negative T cell number J:26250
increased gamma-delta T cell number J:26250
increased urine protein level J:45448
kidney inflammation J:45448
premature death J:26250
Faslpr/Faslpr
involves: C3H * MRL/Mp
abnormal stria vascularis morphology J:1060, J:34296
abnormal stria vascularis vasculature morphology J:34296
autoimmune response J:1060
increased anti-nuclear antigen antibody level J:34296
increased or absent threshold for auditory brainstem response J:1060, J:34296
increased spleen weight J:34296
increased susceptibility to systemic lupus erythematosus J:34296
increased susceptibility to type III hypersensitivity reaction J:34296
Faslpr/Faslpr
involves: C57BL/6 * MRL/Mp
enlarged spleen J:73396
increased anti-double stranded DNA antibody level J:73396
increased anti-single stranded DNA antibody level J:73396
increased IgA level J:73396
increased IgG1 level J:73396
increased IgG2a level J:73396
increased IgG2b level J:73396
increased IgG3 level J:73396
increased IgM level J:73396
lymph node hyperplasia J:73396
Faslpr/Faslpr
involves: MRL/Mp
decreased macrophage apoptosis J:154647
increased susceptibility to bacterial infection J:50903
increased susceptibility to induced morbidity/mortality J:50903
Faslpr/Faslpr
MRL-Faslpr
abnormal T-helper 2 physiology J:6257
enlarged lymph nodes J:126261
glomerulonephritis J:126261
increased anti-double stranded DNA antibody level J:126261
increased anti-nuclear antigen antibody level J:126261
increased blood urea nitrogen level J:126261
increased IgG level J:126261
increased IgM level J:126261
increased immunoglobulin level J:6257
increased spleen weight J:126261
vascular inflammation J:126261
Faslpr/Faslpr
MRL.Cg-Irf1tm1Mak Faslpr
abnormal skin condition J:114771
epidermal necrosis J:114771
glomerulonephritis J:114771
increased anti-double stranded DNA antibody level J:114771
increased urine protein level J:114771
kidney failure J:114771
premature death J:114771
renal glomerular immunoglobulin deposits J:114771
skin lesions J:114771
Faslpr/Faslpr
MRL.Cg-Tnfrsf9tm1Byk Faslpr
premature death J:127197
skin lesions J:127197
Faslpr/Faslpr
MRL/Mp-Agtpbp1atms Faslpr
enlarged lymph nodes J:103944
enlarged spleen J:103944
enlarged thymus J:103944
increased body weight J:103944
increased tumor incidence J:103944
ruffled hair J:103944
Faslpr/Faslpr
MRL/Mp-Faslpr
abnormal B cell morphology J:108760
abnormal B cell receptor editing J:131138
abnormal cardiovascular system physiology J:27634
abnormal circulating protein level J:27634
abnormal coronary artery morphology J:27634
abnormal cytotoxic T cell physiology J:7488
abnormal gland morphology J:18512
abnormal glomerular capillary endothelium morphology J:28885
abnormal glomerular capillary morphology J:28885
abnormal immune system organ morphology J:28885
abnormal immune system physiology J:28885
abnormal interleukin level J:8267
abnormal lymph node cell ratio J:6257
abnormal lymph node morphology J:27634
abnormal marginal zone B cell morphology J:131138
abnormal submandibular gland morphology J:18512
abnormal T cell morphology J:8267, J:108760
abnormal T cell physiology J:8267
abnormal T cell proliferation J:8267
abnormal T-helper 2 physiology J:6257
abnormal thymus medulla morphology J:28885
abnormal thyroid follicle morphology J:28171
abnormal thyroid gland morphology J:28171
abnormal type III hypersensitivity reaction J:28885
blood vessel inflammation J:28885
decreased interleukin-2 secretion J:6638, J:7488
normal endocrine/exocrine gland phenotype J:18512
enlarged lymph nodes J:13757, J:27634, J:28885, J:108760
enlarged Peyer's patches J:28885
enlarged spleen J:28885
enlarged thymus J:13757
glomerular crescent J:28885
glomerulonephritis J:13757, J:27634, J:28885
increased anti-double stranded DNA antibody level J:6257, J:27634, J:131138
increased anti-erythrocyte antigen antibody level J:27634
increased anti-nuclear antigen antibody level J:27634, J:28885
increased anti-single stranded DNA antibody level J:27634
increased autoantibody level J:28885
increased circulating serum albumin level J:28885
increased circulating total protein level J:28885
increased IgA level J:28885
increased IgG1 level J:13757, J:28885
increased IgG2a level J:13757, J:28885
increased IgG2b level J:28885
increased IgG level J:27634
increased IgM level J:28885
increased immunoglobulin level J:6257, J:13757, J:28885
increased kidney cell proliferation J:27634
increased mesangial cell number J:28885
increased renal glomerulus basement membrane thickness J:28885
increased susceptibility to autoimmune disorder J:108760
increased thymus weight J:28885
increased urine protein level J:28885
joint swelling J:27634
lacrimal gland inflammation J:18512
lymph node hemorrhage J:27634
lymph node hyperplasia J:27634
lymph node necrosis J:27634
premature death J:13757, J:27634, J:28885
renal cast J:28885
renal glomerular immunoglobulin deposits J:13757, J:27634
renal glomerular protein deposits J:27634
salivary gland inflammation J:18512
skin lesions J:28885
submandibular gland inflammation J:21965
thymus atrophy J:27634
thymus cortex atrophy J:13757, J:28885
thyroid gland inflammation J:28171
Faslpr/Faslpr
MRL/MpJ-Faslpr
abnormal leukocyte adhesion J:126009
abnormal leukocyte morphology J:126009
autoimmune response J:125114
blood vessel inflammation J:137066
decreased activated T cell number J:137066
decreased B cell number J:137066
decreased CD4-positive, alpha-beta T cell number J:137066
decreased CD8-positive, alpha-beta T cell number J:137066
enlarged lymph nodes J:137066
enlarged spleen J:137066
glomerulonephritis J:125114, J:132514, J:137066
impaired leukocyte tethering or rolling J:126009
increased anti-nuclear antigen antibody level J:137066
increased autoantibody level J:137066
increased double-negative T cell number J:137066
increased immunoglobulin level J:125114
premature death J:125114, J:137066
renal glomerular immunoglobulin deposits J:125114
Faslpr/Faslpr
MRL/MpJ-Faslpr/J
abnormal conjunctival epithelium morphology J:123192
abnormal enzyme/coenzyme activity J:109815
abnormal immunoglobulin level J:122315
abnormal kidney physiology J:127199
abnormal myocardium layer morphology J:14151
abnormal renal glomerulus morphology J:7454, J:127199
abnormal spatial learning J:14151
abnormal stria vascularis morphology J:3638
abnormal strial intermediate cell morphology J:3638
albuminuria J:122315
CNS inflammation J:14151
conjunctivitis J:123192
cortical renal glomerulopathies J:122315
decreased IgG level J:122315
decreased immature B cell number J:122315
decreased marginal zone B cell number J:122315
decreased mature B cell number J:122315
decreased spleen germinal center number J:122315
decreased transitional stage B cell number J:122315
dilated renal glomerular capsule J:122315
enlarged lymph nodes J:7454, J:92084
expanded mesangial matrix J:127199
glomerular crescent J:122315
glomerulonephritis J:7454, J:92084, J:122315, J:127199
impaired coordination J:14151
increased anti-double stranded DNA antibody level J:7454, J:92084, J:122315
increased anti-nuclear antigen antibody level J:7454, J:14151, J:92084, J:111811
increased autoantibody level J:14151, J:92084
increased IgG level J:92084
increased immunoglobulin level J:7454, J:122315
increased mesangial cell number J:127199
increased neutrophil cell number J:127199
increased or absent threshold for auditory brainstem response J:3638
increased plasma cell number J:122315
increased susceptibility to systemic lupus erythematosus J:92084
increased urine protein level J:92084, J:122315
lymph node hemorrhage J:7454
lymph node necrosis J:7454
podocyte foot process effacement J:127199
premature death J:7454
renal glomerulus hypertrophy J:122315
salivary gland inflammation J:92084
vascular inflammation J:127199
normal vision/eye phenotype J:123192
Faslpr/Faslpr
NOD.MRL(B6)-Faslpr
decreased susceptibility to autoimmune diabetes J:64051
Faslpr/Faslpr
NOD.MRL-Faslpr
decreased susceptibility to autoimmune diabetes J:78679
Faslpr/Fastm1.1Cgn
involves: C57BL/6 * MRL
abnormal immune system morphology J:114948
enlarged lymph nodes J:114948
enlarged spleen J:114948
Faslpr/Fastm1Cgn
Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * DBA/2 * MRL
enlarged lymph nodes J:114948
enlarged spleen J:114948
increased double-negative T cell number J:114948
Fasm1Btlr/Fasm1Btlr
C57BL/6J-Fasm1Btlr
decreased CD4-positive, alpha-beta T cell number J:216052
decreased CD8-positive, alpha-beta T cell number J:216052
increased neutrophil cell number J:216052
increased NK cell number J:216052
Fasm2Btlr/Fasm2Btlr
C57BL/6J-Fasm2Btlr
increased central memory CD4-positive, alpha-beta T cell number J:271891
increased effector memory CD4-positive, alpha-beta T cell number J:271891
Fastheo/Fastheo
either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu)
enlarged lymph nodes J:104190
increased anti-nuclear antigen antibody level J:104190
Fastm1.1(ALPP)Chnd/Fastm1.1(ALPP)Chnd
involves: C57BL/6 * SJL
no abnormal phenotype detected J:101977
Fastm1.1Cgn/Fastm1.1Cgn
involves: C57BL/6
abnormal immune system morphology J:114948
enlarged lymph nodes J:114948
enlarged spleen J:114948
Fastm1Ach/Fastm1Ach
Tg(GZMB-cre)1Jcb/?
involves: C57BL/6 * FVB/N
increased anti-nuclear antigen antibody level J:123556
increased double-positive T cell number J:123556
Fastm1Ach/Fastm1Ach
Tg(Itgax-cre,-EGFP)4097Ach/?
Not Specified
abnormal liver morphology J:123556
abnormal spleen morphology J:123556
abnormal spleen periarteriolar lymphoid sheath morphology J:123556
decreased apoptosis J:123556
enlarged spleen J:123556
increased anti-nuclear antigen antibody level J:123556
increased dendritic cell number J:123556
increased IgG level J:123556
increased IgM level J:123556
increased immunoglobulin level J:123556
Fastm1Ach/Fastm1Ach
Tg(Lck-cre)548Jxm/?
involves: C57BL/6 * CBA
increased anti-nuclear antigen antibody level J:123556
increased double-positive T cell number J:123556
Fastm1Cgn/Fastm1Cgn
C57BL/6-Fastm1Cgn
normal immune system phenotype J:114948
Fastm1Cgn/Fastm1Cgn
Cd19tm1(cre)Cgn/Cd19+
Tg(Cd4-cre)1Cwi/0
B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn
increased anti-single stranded DNA antibody level J:114948
Fastm1Cgn/Fastm1Cgn
Mogtm1(cre)Gkl/Mog+
involves: C57BL/6
decreased susceptibility to experimental autoimmune encephalomyelitis J:114741
normal immune system phenotype J:114741
Fastm1Cgn/Fastm1Cgn
Tg(Cd4-cre)1Cwi/0
B6.Cg-Tg(Cd4-cre)1Cwi Fastm1Cgn
abnormal immune system cell morphology J:114948
abnormal immune system organ morphology J:114948
abnormal thymus involution J:114948
alveolitis J:114948
decreased B cell number J:114948
decreased T cell number J:114948
enlarged spleen J:114948
increased activated T cell number J:114948
increased anti-single stranded DNA antibody level J:114948
increased double-negative T cell number J:114948
increased inflammatory response J:114948
increased memory T cell number J:114948
increased T cell apoptosis J:114948
kidney inflammation J:114948
liver inflammation J:114948
lung inflammation J:114948
lymph node hypoplasia J:114948
premature death J:114948
pulmonary fibrosis J:114948
spleen hypoplasia J:114948
weight loss J:114948
Fastm1Cgn/Fastm1Cgn
Tg(Lck-cre)I57Jxm/0
B6.Cg-Fastm1Cgn Tg(Lck-cre)I57Jxm
lymph node hypoplasia J:114948
Fastm1Cgn/Fastm1Cgn
Tg(Mx1-cre)1Cgn/0
B6.Cg-Fastm1Cgn Tg(Mx1-cre)1Cgn
abnormal immune system morphology J:114948
enlarged lymph nodes J:114948
enlarged spleen J:114948
Fastm1Dlo/Fastm1Dlo
involves: 129P2/OlaHsd * C57BL/6
abnormal apoptosis J:90750
abnormal thymus involution J:90750
enlarged lymph nodes J:31847
enlarged spleen J:31847
increased immunoglobulin level J:31847
Fastm1Osa/Fastm1Osa
involves: 129P2/OlaHsd * C57BL/6
abnormal hepatocyte morphology J:64296
abnormal hypersensitivity reaction J:32125, J:64296
abnormal lymph organ size J:64296
abnormal T cell clonal deletion J:32125
enlarged lymph nodes J:32125, J:64296
enlarged spleen J:32125, J:64296
increased anti-double stranded DNA antibody level J:32125
increased anti-single stranded DNA antibody level J:32125
increased autoantibody level J:32125
increased B cell number J:32125
increased IgG1 level J:32125
increased IgG2a level J:32125
increased IgG2b level J:32125
increased IgG3 level J:32125
increased IgG level J:32125
increased leukocyte cell number J:32125
increased lymphocyte cell number J:32125, J:64296
increased susceptibility to parasitic infection J:81397
liver hyperplasia J:64296
lymphoid hyperplasia J:64296
premature death J:64296

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
10/29/2024
MGI 6.24
The Jackson Laboratory